These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8992873)

  • 1. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
    Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
    J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
    Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
    J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
    Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
    Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis.
    Ibbotson KJ; Orcutt CM; D'Souza SM; Paddock CL; Arthur JA; Jankowsky ML; Boyce RW
    J Bone Miner Res; 1992 Apr; 7(4):425-32. PubMed ID: 1609630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
    Cosman F; Nieves J; Shen V; Lindsay R
    J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin.
    French DL; Muir JM; Webber CE
    Phytomedicine; 2008 Dec; 15(12):1069-78. PubMed ID: 18693096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation.
    Hashimoto T; Shigetomi M; Ohno T; Matsunaga T; Muramatsu K; Tanaka H; Sugiyama T; Taguchi T
    Calcif Tissue Int; 2007 Sep; 81(3):232-9. PubMed ID: 17674071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
    Uretmen S; Gol M; Cimrin D; Irmak E
    Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
    Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
    J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.
    Kulkarni NH; Wei T; Kumar A; Dow ER; Stewart TR; Shou J; N'cho M; Sterchi DL; Gitter BD; Higgs RE; Halladay DL; Engler TA; Martin TJ; Bryant HU; Ma YL; Onyia JE
    J Cell Biochem; 2007 Dec; 102(6):1504-18. PubMed ID: 17520664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model.
    Abe Y; Takahata M; Ito M; Irie K; Abumi K; Minami A
    Bone; 2007 Nov; 41(5):775-85. PubMed ID: 17707711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
    Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
    Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.